Pulse lineResearch With Heart Logo

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.

TitlePlasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.
Publication TypeJournal Article
Year of Publication2012
AuthorsVoight BF, Peloso GM, Orho-Melander M, et al.
Secondary AuthorsKathiresan S
JournalLancet
Volume380
Issue9841
Pagination572-80
Date Published2012 Aug 11
ISSN1474-547X
KeywordsBiomarkers, Case-Control Studies, Cholesterol, HDL, Cholesterol, LDL, Gene Frequency, Genetic Predisposition to Disease, Humans, Lipase, Mendelian Randomization Analysis, Myocardial Infarction, Polymorphism, Single Nucleotide, Prospective Studies, Risk Factors
Abstract

BACKGROUND: High plasma HDL cholesterol is associated with reduced risk of myocardial infarction, but whether this association is causal is unclear. Exploiting the fact that genotypes are randomly assigned at meiosis, are independent of non-genetic confounding, and are unmodified by disease processes, mendelian randomisation can be used to test the hypothesis that the association of a plasma biomarker with disease is causal.

METHODS: We performed two mendelian randomisation analyses. First, we used as an instrument a single nucleotide polymorphism (SNP) in the endothelial lipase gene (LIPG Asn396Ser) and tested this SNP in 20 studies (20,913 myocardial infarction cases, 95,407 controls). Second, we used as an instrument a genetic score consisting of 14 common SNPs that exclusively associate with HDL cholesterol and tested this score in up to 12,482 cases of myocardial infarction and 41,331 controls. As a positive control, we also tested a genetic score of 13 common SNPs exclusively associated with LDL cholesterol.

FINDINGS: Carriers of the LIPG 396Ser allele (2·6% frequency) had higher HDL cholesterol (0·14 mmol/L higher, p=8×10(-13)) but similar levels of other lipid and non-lipid risk factors for myocardial infarction compared with non-carriers. This difference in HDL cholesterol is expected to decrease risk of myocardial infarction by 13% (odds ratio [OR] 0·87, 95% CI 0·84-0·91). However, we noted that the 396Ser allele was not associated with risk of myocardial infarction (OR 0·99, 95% CI 0·88-1·11, p=0·85). From observational epidemiology, an increase of 1 SD in HDL cholesterol was associated with reduced risk of myocardial infarction (OR 0·62, 95% CI 0·58-0·66). However, a 1 SD increase in HDL cholesterol due to genetic score was not associated with risk of myocardial infarction (OR 0·93, 95% CI 0·68-1·26, p=0·63). For LDL cholesterol, the estimate from observational epidemiology (a 1 SD increase in LDL cholesterol associated with OR 1·54, 95% CI 1·45-1·63) was concordant with that from genetic score (OR 2·13, 95% CI 1·69-2·69, p=2×10(-10)).

INTERPRETATION: Some genetic mechanisms that raise plasma HDL cholesterol do not seem to lower risk of myocardial infarction. These data challenge the concept that raising of plasma HDL cholesterol will uniformly translate into reductions in risk of myocardial infarction.

FUNDING: US National Institutes of Health, The Wellcome Trust, European Union, British Heart Foundation, and the German Federal Ministry of Education and Research.

DOI10.1016/S0140-6736(12)60312-2
Alternate JournalLancet
PubMed ID22607825
PubMed Central IDPMC3419820
Grant ListU01 HG006513 / HG / NHGRI NIH HHS / United States
RG/08/014/24067 / / British Heart Foundation / United Kingdom
R01 DK072193 / DK / NIDDK NIH HHS / United States
N01 HC025195 / HC / NHLBI NIH HHS / United States
MC_U137686857 / / Medical Research Council / United Kingdom
090532 / / Wellcome Trust / United Kingdom
R00 HL094535 / HL / NHLBI NIH HHS / United States
UL1 RR024148 / RR / NCRR NIH HHS / United States
P30 DK020572 / DK / NIDDK NIH HHS / United States